Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of weekly survodutide in compensated MASH cirrhosis
CTR20244843Phase 3Active
- Sponsor
- ——/ 勃林格殷格翰(中国)投资有限公司
- Start
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), Cirrhosis, sponsored by ——/ 勃林格殷格翰(中国)投资有限公司. Started May 2025; status: active.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on CTR20244843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244843.